4 completed, 1 recruiting, 1 terminated. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer VLS-1488 - Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary | Phase 1 / Phase 2 | Recruiting | Volastra Therapeutics, Inc. | 200 | 2023-10-18 | 2025-11-04 |
| Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers Entinostat, Olaparib - Fallopian Tube Cancer, Fallopian Tube Carcinosarcoma | Phase 1 | Terminated | Vanderbilt-Ingram Cancer Center | 3 | 2020-10-01 | 2022-04-04 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Adjuvant Therapy, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Infectious Disorder | Phase 1 | Completed | Gynecologic Oncology Group | 43 | 2006-06-01 | 2014-12-31 |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) carboplatin, paclitaxel, docetaxel - Brenner Tumor, Fallopian Tube Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-05-01 | 2019-07-22 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (3) · Brenner Tumor (2) · Endometrial Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Chromosomal Instability (1) · Communicable Diseases (1) · Neutropenia (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Fallopian Tube Diseases (4) · Gonadal Disorders (4) · Ovarian Diseases (4)
Taxes (4) · Bevacizumab (3) · Carboplatin (3) · Paclitaxel (3) · Disulfides (2) · Immunoglobulin G (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Chemotherapy, Adjuvant (1) · Cisplatin (1) · Docetaxel (1) · Platinum (1) · entinostat (1) · olaparib (1)
National Cancer Institute (NCI) (2) · Gynecologic Oncology Group (1) · Mayo Clinic (1) · Vanderbilt-Ingram Cancer Center (1) · Volastra Therapeutics, Inc. (1)
United States (6)
Amy Tiersten (1) · Joan Walker (1) · Katherine M Bell-McGuinn (1) · Marta Crispens, MD (1) · Matthew S. Block, M.D., Ph.D. (1)
U10CA027469 (3), U10CA180868 (1)